Clearside (CLSD) Company Long-Term Loans and Borrowings

Clearside Biomedical Inc - graphic logo of issuer CLSD

Clearside Biomedical (CLSD) revenues are based on licensing payments for the use of the patented XIPERE device, with the figure standing at 0.00. The company is developing a comprehensive therapy system where the SCS Microinjector platform ensures high-precision drug delivery for retinal edema. This price action chart is supplemented by data on the robotization of assembly lines, which minimizes manual labor in the production of microinjectors.

CLSD Clearside Biomedical: Company Long-Term Debts in the range 07/04/2022 - 12/13/2025

Financial and market metric breakdowns for Clearside (CLSD)

- price and consensus price forecast:
Stock Price clearsidebio.com|CLSD - Price Target Chart
- market capitalization data:
Market Value Clearside Biomedical|CLSD - Total Company Value
- book capitalization data:
Accounting Value per Share Clearside Biomedical|CLSD - Book Capitalization|Market Capitalization to Book Value Ratio clearsidebio.com|CLSD - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Clearside Biomedical|CLSD - Long-Term Debt to Capital|Current Liabilities to Capital Clearside Corp|CLSD - Company Total Debt|Debts to Book Value Clearside Biomedical|CLSD - Company Long-Term Debts|Short-Term Debt Clearside Biomedical
Fundamental valuation:CLSD (clearsidebio.com)
Original product of Clearside Biomedical, Inc.

Clearside Biomedical (CLSD) is developing innovative ophthalmological drugs amidst fierce competition and a heavy reliance on clinical trial results. This metric measures the total volume of long-term liabilities, enabling an assessment of capital structure stability and default risk via GURU.Markets tools by analyzing the company's current level of long-term debt as an indicator of the biopharmaceutical business's financial autonomy.

Direct competitors

alcon.com - Company Long-Term Debts|Company Long-Term Debt Bausch + Lomb (BLCO)|GKOS: Company Long-Term Loans and Borrowings|APLS (Apellis Pharmaceuticals Inc) - Company Long-Term Debt|Belite Bio, Inc. (BLTE) - Company Long-Term Liabilities|OCUL (Ocular Therapeutix) - Company Long-Term Debts|Company Long-Term Debts harrowinc.com (HROW)|Viridian Therapeutics, Inc. (VRDN) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings LENZ Therapeutics Inc (LENZ)|OCS: Company Long-Term Debts|EYPT - Long-Term Debt|KOD (Kodiak Sciences Inc.) - Company Long-Term Liabilities|ALDX - Long-Term Debt|Company Long-Term Debts KALA|IRD (Opus Genetics) - Long-Term Debt|OKYO: Company Long-Term Debt|Long-Term Debt Volume Adverum|Company Long-Term Debts OTLK (Outlook Therapeutics)|Company Long-Term Liabilities NBY (novabay.com)|Company Long-Term Debt Kiora Pharmaceuticals, Inc. KPRX|Company Long-Term Debt Alimera Sciences Inc ALIM|EYEN (Eyenovia Corp) - Company Long-Term Debts|GHSI - Long-Term Debt|OCUP: Company Long-Term Debts|OPT (opthea.com) - Company Long-Term Debts